Evaluation of optimal 5ASA dose in order to determine for keeping remission of patients with ulcerative colitis by colonoscopy using FICE (flexible spectral imaging color enhancement) system.

Evaluation of optimal 5ASA dose in order to determine for keeping remission of patients with ulcerative colitis by colonoscopy using FICE (flexible spectral imaging color enhancement) system. - Determination of optimal 5ASA dose for keeping remission of UC patients by FICE colonoscopy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005270

Enrollment

180

Registered

2011-04-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

GroupA:Pentasa4g/day or Asacol 3.6g/day (VS&gt

5),same dose GroupB:Pentasa4g/day or Asacol 3.6g/day (VS=5),same dose GroupC:Pentasa4g/day or Asacol 3.6g/day (VS=5), decrease dose to Pentasa3g/day or Asacol 2.4g/day GroupD:Pentasa2-3g/day or

5), same dose GroupE:Pentasa2-3g/day or Asacol 2.4g/day (VS&gt

5), increase dose to Pentasa4g/day or Asacol 3.6g/day GroupF:Pentasa2-3g/day or Asacol 2.4g/day (VS=5),same dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with quiescent ulcerative colitis who can accept colonoscopy Patients whose CAI is 3 or less Patients who takes mesalazine

Exclusion criteria

Exclusion criteria: Patients who cannot accept colonoscopy Patients who have no agreement of this study Patients who is pregnant or possibly be pregnant Patients who had operation of total or partial colectomy Patients who got to start to take treamtents such as; -sterids (intravenous, peroral, enema and suppo) within 4 weeks -metrinidazole within 4 weeks -infliximab within 4 weeks -elemental diet or IVH within 4 weeks -cyclosporine or tacrolimus within 4 weeks -azathiopurine or 6MP within 4 weeks -mesalazine enema or suppo within 4 weeks -increase or decrease the mesalazine dose within 4 weeks

Design outcomes

Primary

Measure	Time frame
non-relapse rate by CAI score after one year	—

Secondary

Measure	Time frame
clinical Activity Index (CAI) vascular grading (VG) vascular score (VS) non-relapse rate after 3,6,9 months inflammatory response score(WBC, Plt, ESR, CRP) pathological Matts gradings safety remission period (month)	—

Countries

Japan

Contacts

Public ContactShingo kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp+81-49-228-3564

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026